Associated Papers
Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients.
Vucicevic K et al.
Cureus, 2025
Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.
Khan A et al.
Global Medical Genetics, 2022
Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.
Aiuchi N et al.
Pharmacology Research & Perspectives, 2022
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.
Dagli-Hernandez C et al.
Pharmacological Reports : Pr, 2022
Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.
Nwogu JN et al.
Aids (london, England), 2021
Differential Effects of Components in Artemisia annua Extract on the Induction of Drug-Metabolizing Enzyme Expression Mediated by Nuclear Receptors.
Zhang X et al.
Planta Medica, 2020
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Adegbola AJ et al.
Pharmacogenetics and Genomics, 2020
Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients.
Thomas L et al.
Antibiotics (basel, Switzerland), 2020
A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
Patel RC et al.
Aids (london, England), 2019
Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
Ayuso P et al.
The Journal of Antimicrobial Chemotherapy, 2019
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
Neary M et al.
Clinical Pharmacology and Therapeutics, 2017
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
Calcagno A et al.
Clinical Pharmacokinetics, 2017
Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol.
Gonzalez-Covarrubias V et al.
Frontiers in Pharmacology, 2017
Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.
Olagunju A et al.
Pharmacogenetics and Genomics, 2016
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Dickinson L et al.
Clinical Pharmacokinetics, 2016
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.
Bienczak A et al.
British Journal of Clinical Pharmacology, 2016
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L et al.
Clinical Pharmacology and Therapeutics, 2015
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2015
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM et al.
Pharmacogenetics and Genomics, 2015
Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju A et al.
Clinical Pharmacology and Therapeutics, 2015
Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects.
Zang M et al.
Drug Metabolism and Pharmacokinetics, 2015
Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.
Lima LO et al.
Arquivos Brasileiros De Endocrinologia E Metabologia, 2013
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C et al.
The Journal of Antimicrobial Chemotherapy, 2011